In particular, one patient in the latter study, who had advanced and hormonal resistant prostate cancer, had a 50% decrease in serum PSA level with significant improvement in his quality of life and decrease of pain after 16 weeks of treatment. This evidence concerns the gene KLK3 and prostate cancer.